Patents Assigned to SIMCERE PHARMACEUTICAL CO., LTD.
  • Pyrazolopyrimidine derivative and use thereof
    Patent number: 11464780
    Abstract: A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: October 11, 2022
    Assignee: Simcere Pharmaceutical Co. Ltd.
    Inventors: Jianfei Wang, Jikui Sun, Wenyuan Zhu, Yang Zhang, Jie Li, Jian Li, Shuhui Chen
  • Antitumor compound for activating gene and degrading HER2, preparation method thereof, and application thereof
    Patent number: 11427575
    Abstract: A compound as shown in formula I. R1 is selected from the group consisting of —OH, —CH3, —CH2CH3, —OCH3, —OCH2CH3; R2 is selected from the group consisting of —H, —OH, —CH3, —CH2CH3, —CH2CH2CH3, —OCH3, —OCH2CH2CH3; R3 is selected from the group consisting of —F, —Cl, —Br, —I, —CF3; R4 is selected from the group consisting of —H, —F, —Cl, —Br, —I, —CF3; and R5 is selected from the group consisting of —H, —CH3, —CH2CH3.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 30, 2022
    Assignee: SIMCERE PHARMACEUTICAL CO., LTD.
    Inventor: Jianwei Zhou
  • Sublingual pharmaceutical compositions of edaravone and (+)-2-borneol
    Patent number: 11135199
    Abstract: A sublingual tablet pharmaceutical composition containing edaravone and (+)-2-borneol, and a preparation method thereof. The sublingual tablet pharmaceutical composition includes edaravone, (+)-2-camphanol, an excipient, a filler, a binder, a disintegrant, and a lubricant. The excipient is selected from one or more of mannitol, lactose, dextran, cysteine, glycine, copovidone, and beta-cyclodextrin.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: October 5, 2021
    Assignees: NEURODAWN PHARMACEUTICAL CO., LTD., SIMCERE PHARMACEUTICAL CO., LTD.
    Inventor: Yijun Wang
  • Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis
    Patent number: 10206905
    Abstract: The present invention relates to the use of a composition for preparing a medicament for the treatment of amyotrophic lateral sclerosis and associated disorders. The composition comprises 3-methyl-1-phenyl-2-pyrazoline-5-one or pharmaceutically acceptable salts thereof and borneol. The medicament is a drug used for delaying the occurrence time of amyotrophic lateral sclerosis and extending the survival time, and for improving memory function defect of amyotrophic lateral sclerosis.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: February 19, 2019
    Assignee: JIANGSU SIMCERE PHARMACEUTICAL CO., LTD
    Inventors: Shibao Yang, Yao Hua, Zhengping Zhang, Rong Chen, Zhaolong Gong